Biochemical Engineering Special Interest Group
biological engineering professionals
18 January 2016

Shire announces $32B deal to acquire Baxalta

Shire will purchase Baxalta in a cash-and-stock deal worth $32 billion, the companies announced Monday. The acquisition, expected to be completed in the middle of this year, will form the largest rare disease treatment developer in the world, the firms say. Baxalta shareholders could receive $45.57 per share and will own a 34% stake in the combined company. Source: Smartbrief. 18/1/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).